Skip to main content
Premium Trial:

Request an Annual Quote

TGen in Infrastructure, Informatics Partnership with IBM

NEW YORK, April 25 - Arizona's Translational Genomics Research Institute (Tgen), along with Arizona State University and the International Genomics Consortium have signed on to a collaborative technology deal with IBM, Tgen said today.

 

Under the agreement, IBM will provide supercomputing infrastructure to Tgen, of Phoenixwhich will be housed at the neighboring university, ASU. The partners will "explore" joint research including computational analysis of gene expression under various conditions, according to Tgen. The research will focus on diseases such as cancer, diabetes, Alzheimer's and Parkinson's disease.

 

The infrastructure will include a 512-node cluster of IBM eServer xSeries 1350 servers that run the Linux operating system, as well as six IBM eServer pSeries servers for UNIX operating systems.   IBM will also provide its TotalStorage FAStT700 disk storage system, which enables access and retrieval of massive volumes of information, as well as the IBM TotalStorage Ultrascalable Linear Tape-Open Tape Library, for centralized data backup, and the Tivoli Storage Manager.

 

The researchers are also using IBM's [email protected] algorithms to map molecular markers of cancer. In an initial phase, researchers are performing comparative analysis of cells from responders to treatment with those who did not respond well.

 

For more information on Tgen, go to http://www.tgen.org.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.